Crinetics Pharmaceuticals (CRNX) Q2 2024 earnings summary

Executive summary

• Positive phase II results for atumelnant in congenital adrenal hyperplasia and Cushing's disease, and robust phase III data for paltusotine in acromegaly, reinforce confidence in the pipeline.

• NDA filing for paltusotine in acromegaly is on track for H2 2024, with a commercial launch anticipated in 2025 and a phase III trial in carcinoid syndrome planned by year-end.

• Early-stage pipeline includes a PTH receptor antagonist for hyperparathyroidism and an SST3 agonist for ADPKD, with IND-enabling studies underway.

• Strategic partnership with Radionetics Oncology and Eli Lilly could yield significant non-dilutive funding and validates the discovery platform.

• CFO Marc Wilson announced his departure for personal reasons; a search for his successor is underway.

Financial highlights

• Ended Q2 2024 with $863 million in cash, cash equivalents, and investments, projected to fund operations into 2028.

• Q2 2024 research and development expenses were $58.3 million, up from $40.6 million year-over-year.

• General and administrative expenses rose to $24.8 million from $13.3 million year-over-year.

• Net loss for Q2 2024 was $74.1 million, compared to $51 million in Q2 2023.

• Revenues were $0.4 million, down from $1 million year-over-year, primarily from a licensing arrangement.

Outlook and guidance

• NDA submission for paltusotine in acromegaly expected in H2 2024; commercial launch anticipated in 2025.

• Phase III trial for paltusotine in carcinoid syndrome planned to start by end of 2024.

• Additional phase II data for atumelnant in CAH and Cushing’s disease expected by end of 2024, with phase III design discussions to follow.

• IND filing for the PTH antagonist program anticipated in 2025.

• Cash reserves expected to fund operations into 2028.